Dopamine D2 receptor polymorphisms in inflammatory bowel disease and the refractory response to treatment

Digestive Diseases and Sciences

Volumn 51, Issue 11, 2006, Pages 2039-2044

  Magro, F ^a,b,f   Cunha, E ^c   Araujo, F ^d   Meireles, E ^d   Pereira, P ^a   Dinis Ribeiro, M ^e   Veloso, F Tavarela ^a   Medeiros, R ^c   Soares Da Silva, P ^b  

^a Gastroenterology Department   (Portugal)

^b Inst of Pharmacol and Therapeutics   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d HOSPITAL DE SÃO JOÃO   (Portugal)

^e Inst of Pharmacol and Therapeutics   (Portugal)

^f NONE   (Portugal)

Author keywords

Crohn's disease; Dopamine; Inflammatory bowel disease; Polymorphism; Refractory disease

Indexed keywords

AZATHIOPRINE; CIPROFLOXACIN; CORTICOSTEROID; CYCLOSPORIN; DOPAMINE; DOPAMINE 2 RECEPTOR; INFLIXIMAB; MESALAZINE; METRONIDAZOLE;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE COURSE; ENTERITIS; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR DENSITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; ULCERATIVE COLITIS; ADOLESCENT; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, DOPAMINE D2;

EID: 33751531923     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-006-9168-3     Document Type: Article

References (45)

1. Groux H, Powrie F (1999) Regulatory T cells and inflammatory bowel disease. Immunol Today 20:442-445
2. Strober W, Kelsall B, Fuss I, Marth T, Ludviksson B, Ehrhardt R, Neurath M (1997) Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today 18:61-64
3. Stangi J, Parkes M, Louis E (1996) Two stage genoma-with search in inflammatory bowel disease provides evidence for susceptibility loci on chromossoma 3,7 and 12. Nat Genet 14:199-202
4. Hugot JP, Chamaillard M, Zouali H (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411:599-603
5. Ogura Y, Bonen DK, Inohara N (2001) A frameshift mutation in NOD2 associated with susceptibility to Cohn's disease. Nature 411:603-606
6. Ader S, Felton D, Cohn N (1990) Interactions between the brain and the immune system. Annu Rev Pharmacol Toxicol 30:561-602
7. Basu S, Dasgupta PS (2000) Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 102:113-124
8. McKenna F, Mclaughlin PJ, Lweis BJ, Sibbring GC, Cumerson JA, Bowen-Jones D (2002) Dopamine receptor expression on human T and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 132:34-40
9. Ricci A, Vegilio F, Amenta F (1995) Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with 3H-7-OH-DPAT. J Neuroimmunol 58:139-144
10. Bergquist J, Tarkowski A, Ekman R, Ewing A (1994) Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamines regulation of lymphocytes function via an autocrine loop. Proc Natl Acad Sci USA 91:12912-12916
11. Magro F, Vieira-Coelho MA, Fraga S, Serrao MP, Veloso FT, Ribeiro T, Soares-da-Silva P (2002) Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 47:216-224
12. Magro F, Fraga S, Ribeiro T, Soares-da-Silva P (2004) Decreased availability of intestinal dopamine in transmural colitis may relate to inhibitory effects of interferon-gammaupon L-dopa uptake. Acta Physiol Scand 180:379-386
13. Harvey RF, Bradshaw JM (1980) A simple index of Crohn's disease activity. Lancet 1(8167):514
14. Irvine EJ (1995) Usual therapy improves Crohn's disease as measure a new disease activity index. McMaster Study Group. J Clin Gastroenterol 20:27-32
15. Truelove SC, Witts LJ (1995) Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 4947:1041-1048
16. Munkholm P, Langholz E, Davidsen M, Binder V (1994) Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 35:360-362
17. Potocnik U, Ferkolj I, Glavac D, Dean M (2004) Polymorphisms in multidrug resistance 1 (MDR1) gene are associated with refractory Crohn's disease and ulcerative colitis. Genes and Immunity 5:530-539
18. Spitz MR, Shi H, Yang F, Hudmon KS, Jiang H, Chamberlain RM, Amos CI, Wan Y, Cinciripini P, Hong WK, Wu X (1998) Case-control study of the D2 dopamine receptor gene and smoking status in lung cancer patients. J Natl Cancer Inst 90:358-363
19. Niessner M, Volk BA (1995) Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reverse transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101:428-435
20. Breese E, Braegger CP, Corrigan CJ (1993). Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunol Today 78:127-131
21. Papadakis KA, Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51:289-298
22. Peppelenbosch MP, Deventer SJ (2004) T cell apoptosis and inflammatory bowel disease. Gut 53:1556-1558
23. Ghosh MC, Mondal AC, Basu S, Banerjee S, Majumber J, Bhattacharya D, Dasgupta PA (2003) Dopamine inhibits cytokine release and expression of tyrosine kinases, LCK and Fyn in activated T cells. Int Immunopharmacol 3:1019-1026
24. Denny MF, Patai B, Strauss DB (2000) Differential T-cell antigen receptor signaling mediated by Src family kinases Lck and Fyn. Mol Cell Biol 20:1426-1435
25. Qian D, Weiss A (1997) T cell antigen receptor signal transduction. Curr Opin Cell Biol 9:205-212
26. Morikawa K, Oseko F, Morikawa S (1994) Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immunol 95:514-518
27. Riskind PN, Massacesi L, Doolittle TH, Hauser SL (1991) The role of prolactin in autoimmune demyelination: suppression of experimental allergic encepalomyelitis by bromocriptine. Ann Neurol 29:542-547
28. Bergquist J, Josefsson E, Tarkowski A, Ekman R, Ewing A (1997) Measurements of catecholamine-mediated apoptosis of immunocompetent cells by capillary electrophoresis. Electrophoresis 18:1760-1766
29. Colombo C, Cosentino M, Marino F, Rasini E, Ossola M, Blandini F, Mangiagalli A, Samuele A, Ferrari M, Bombelli R, Lecchini S, Nappi G, Frigo G (2003) Dopaminergic modulation of apoptosis in human blood mononuclear cells: possible relevance of Parkinson's disease. Ann N Y Acad Sci 1010:679-682
30. Figueroa FE, Carrion F, Martinnez ME, Rivero S, Mamani L (1997) Bromocriptine induces immunological changes related to disease parameters in rheumatoid arthritis. Br J Rheumatol 36:1022-1023
31. McMurray RW, Weidensaul D, Allen SH, Walker SE (1995) Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus. J Reumatol 22:2084-2091
32. Weber G, Frey H (1987) Treatment of psoriatic arthritis with bromocriptine. J Am Acad Dermatol 16:388-389
33. Kast RE, Altschuler EL (2001) Remission of Crohn's disease on Bupropion. Gastroenterol 121:1260-1261
34. Bergquist J, Silberring J (1998) Identification of catecholamines in the immune system by electrospray ionization mass spectrometry. Rapid Commun Mass Spectrom 12:683-688
35. Josefsson E, Bergquist J, Ekman R, Tarkowski A (1996) Catecholamines are synthesized by mouse lymphocytes and regulate function of these cells by induction of apoptosis. Immunology 88:140-146
36. Tsao CW, Lin YS, Cheng JT (1998) Inhibition of immune cell proliferation with haloporinol and relationship of tyrosine hydroxylase expression to immune cell growth. Life Sci 62:PL335-PL344
37. Ricci A, Bronzetti E, Felici L, Greco S, Amenta F (1998) Labeling of dopamine D3 and D4 receptor subtypes in human peripheral blood lymphocytes with 3H7-OH-DPAT: a combined radioligand binding assay and immunochemical study. J Neuroimmunol 92:191-195
38. Ricci A, Bronzetti E, Mignini F, Tayebati SK, Zaccheo D, Amenta F (1999) Dopamine d1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 96:234-240
39. Levite M, Chowers Y, Ganor Y, Besser M, Hershkovits R, Cahalon L (2001) Dopamine interacts directly with its D3 and D2 receptors on normal human T cells, and activates beta 1 integrin function. Eur J Immunol 31:3504-3512
40. Civelli O, Buzow JR, Grandy DK (1993) Molecular diversity of dopamine receptors. Annu Rev Pharmacol Toxicol 32:281-307
41. Gingrich JA, Caron MG (1993) Recent advances in molecular biology of dopamine receptors. Annu Rev Neurosci 16:299-321
42. Grandy DK, Litt M, Allen L, Bunzow JR, Marchionni M, Makam H, Reed L, Magenis RE, Civelli O (1989) The human D(2) dopamine receptor gene is located on chromosome 11 at q22-q23 and identifies a TaqI RFLP. Am J Hum Genet 45:778-785
43. Noble EP, Blum K, Ritchie T, Montgomery A, Sheridan PJ (1991) Allelic association of the D2 dopamine receptor genewith receptor-binding characteristics in alcoholism. Arch Gen Psych 48:648-654
44. Noble EP, St Jeor ST, Ritchie T, Syndulko K, St Jeor SC, Fitch RJ, Brunner RL, Sparkes RS (1994) D2 dopamine receptor gene and cigarette smoking: a reward gene? Med Hypotheses 42:257-260
45. Epstein LH, Wright SM, Paluch RA, Leddy JJ, Hawk LWJ, Jaroni JL, Saad FG, Crystal-Mansour S, Shields PG, Lerman C (2004) Relation between food reinforcement and dopamine genotypes and its effect on food intake in smokers. Am J Clin Nutr 80:82-88